Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma

Phase 3 Unknown 440 enrolled Zhejiang Cancer Hospital First Affiliated Hospital of Wenzhou Medical University · collab Jinhua Central Hospital · collab Ningbo Medical Center Lihuili Hospital · collab People's Hospital of Quzhou · collab The Central Hospital of Lishui City · collab Zhejiang Provincial People's Hospital · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

In this study, the investigators aim to compare the progression-free survival (PFS) and side effects of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients with a satisfactory tumor response (complete response or partial response) after neoadjuvant chemotherapy (NACT).

Timeline

Start: 2016-12
Primary completion: 2022-12
Completion: 2024-12

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper the premature termination of the trial and insufficient statistical power preclude a definitive noninferiority claim. PMID 42436536 ↗

Publications

Jin T, Jiang F, Jin QF, Hua YH, Jia YS, Du DX, Ding SB, Su HF, Lu MZ, He HJ, Chen XZ. Randomized, multicenter phase 3 study evaluating radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma patients achieving CR/PR after induction chemotherapy. BMC Med. 2026 Jul 11. doi: 10.1186/s12916-026-05064-8. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	75 mg/m2	—
Subject	Cisplatin	Other / unclassified	100 mg/m2	—
Background	Docetaxel	Small molecule	75 mg/m2	—